Research Progress of New State of Pharmaceutical Substance of the Proton Pump Inhibitors
10.3870/j.issn.1004-0781.2025.06.006
- VernacularTitle:质子泵抑制剂的适药新物态研究进展
- Author:
Kun HU
1
;
Wenwen WANG
;
Cheng XING
;
Zhaolin GAO
;
Li ZHANG
;
Yang LYU
Author Information
1. 北京协和医学院·中国医学科学院药物研究所,药物晶型研究中心,晶型药物研究北京市重点实验室,北京 100050
- Publication Type:Journal Article
- Keywords:
Proton pump inhibitors;
New state of pharmaceutical substance;
Polymorphism;
Co-crystal;
Nanomedicine
- From:
Herald of Medicine
2025;44(6):874-881
- CountryChina
- Language:Chinese
-
Abstract:
Currently,the first-generation of proton pump inhibitors(PPIs)commonly utilized in clinical practice for the treatment of peptic ulcer include omeprazole,lansoprazole,and pantoprazole,and the second generation include rabeprazole and esomeprazole.The predominant mode of PPI administration is oral,which poses numerous challenges in clinical settings owing to their poor solubility,susceptibility to gastric acid degradation,short half-life,and limited stability.This article presents a comprehensive review of studies exploring the novel states of these five PPIs,include polymorphism,co-crystal drugs,and nanodrugs.Furthermore,it summarizes the advancements in research aimed at modifying the physicochemical properties of these drugs through innovative solid states,thereby enhancing their bioavailability and stability.This work offers a new perspective for researchers endeavoring to develop new states of pharmaceutical substances that incorporate PPIs.
